{
  "id": "5abbe429fcf456587200001c",
  "type": "factoid",
  "question": "What is the drug target for Eliquis (Apixaban)?",
  "ideal_answer": "The new oral anticoagulants (NOAC) Apixaban (Eliquis) is a direct anti-Xa inhibitors",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27653758",
    "http://www.ncbi.nlm.nih.gov/pubmed/26095540",
    "http://www.ncbi.nlm.nih.gov/pubmed/24624626",
    "http://www.ncbi.nlm.nih.gov/pubmed/26369819",
    "http://www.ncbi.nlm.nih.gov/pubmed/25322783",
    "http://www.ncbi.nlm.nih.gov/pubmed/28439702",
    "http://www.ncbi.nlm.nih.gov/pubmed/23649961",
    "http://www.ncbi.nlm.nih.gov/pubmed/23677804",
    "http://www.ncbi.nlm.nih.gov/pubmed/24711240",
    "http://www.ncbi.nlm.nih.gov/pubmed/23535530",
    "http://www.ncbi.nlm.nih.gov/pubmed/21985171"
  ],
  "snippets": [
    {
      "text": "The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa\u00ae), a direct thrombin inhibitor, and rivaroxaban (Xarelto\u00ae), Apixaban (Eliquis) and Edoxaban (Lixiana\u00ae), which are direct anti-Xa inhibitors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The new direct oral anticoagulants directly targeting thrombin (factor IIa) or factor-Xa, are currently used for the treatment of deep venous thrombosis and pulmonary embolism (rivaroxaban, Xarelto) or for the prevention of systemic embolism in non-valvular atrial fibrillation (rivaroxaban; dabigatran, Pradaxa; Apixaban, Eliquis).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24624626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa) are the new Xa inhibitors that have been recently approved by the U.S. FDA and are in current clinical practice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26369819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The direct factor Xa inhibitor apixaban (Eliquis(\u00ae)) has predictable pharmacodynamics and pharmacokinetics and does not require routine anticoagulation monitoring.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23677804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa\u00ae), a direct thrombin inhibitor, and rivaroxaban (Xarelto\u00ae), Apixaban (Eliquis) and Edoxaban (Lixiana\u00ae), which are direct anti-Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649961",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: apixaban (BMS-562247) (Eliquis(\u00ae)) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "They include the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa, Boehringer Ingelheim) and the oral direct FXa inhibitors rivaroxaban (Xarelto, Bayer HealthCare), apixaban (Eliquis, Bristol-Myers Squibb), and edoxaban (Lixiana/Savaysa, Daiichi-Sankyo).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa) are the new Xa inhibitors that have been recently approved by the U.S. FDA and are in current clinical practice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26369819",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apixaban is the second oral direct selective factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with nonvalvular AF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apixaban (Eliquis\u2122), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21985171",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These specific substances directly block either thrombin (e.g., dabigatran etexilate) or Factor Xa (e.g., apixaban).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28439702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Due to the high protein binding the direkt FXa-inhibitors rivaroxaban (Xarelto\u00ae) and apixaban (Eliquis\u00ae) can not be hemodialysed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24711240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apixaban (Eliquis\u00ae) is an oral, direct factor Xa inhibitor that is available for use in the treatment and secondary prevention of venous thromboembolism (VTE).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27653758",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D065427",
    "http://www.biosemantics.org/jochem#4243936"
  ],
  "exact_answer": "factor Xa"
}